New Australian research published in Cancer Letters suggests that how advanced non-small cell lung cancer (NSCLC) progresses after first-line treatment may offer important prognostic information for clinicians and patients. The study found that the type of lesion driving disease progression — whether growth occurs in existing tumours, new lesions, or both — is associated with differing survival outcomes following initial treatment.
The analysis pooled individual-level data from four large randomised phase III trials evaluating first-line chemotherapy and chemoimmunotherapy regimens in advanced NSCLC. Patients whose disease advanced through existing tumour growth only tended to have the longest median post-progression survival. Those whose progression manifested as new tumour lesions had intermediate outcomes, while patients with both existing and new lesions at progression showed the shortest survival following progression.
CLINICAL SUMMARY
What was examined
A pooled analysis of randomised phase III trials evaluating whether the pattern of tumour progression predicts post-progression survival in patients with advanced non-small cell lung cancer treated with first-line chemotherapy or chemoimmunotherapy.
Key findings
-
Post-progression survival differed according to the lesion type driving disease progression.
-
Progression limited to existing lesions was associated with longer post-progression survival than progression involving new lesions, with the poorest outcomes observed when both existing and new lesions were present.
-
The prognostic impact of progression pattern was observed across treatment arms, including both chemotherapy and chemoimmunotherapy.
Clinical implications
-
Subclassifying disease progression beyond a single “progressive disease” category may provide additional prognostic information in advanced NSCLC.
-
Radiological assessment of progression pattern could help inform expectations following first-line therapy and support more individualised post-progression management.
-
Further validation in real-world cohorts is needed before the progression pattern can be routinely incorporated into clinical decision-making frameworks.
Importantly, the distribution of these progression types was similar regardless of whether patients received chemoimmunotherapy or standard chemotherapy as their initial treatment. The prognostic effect of lesion type was observed across treatment groups, although some differences in magnitude were noted.
The findings suggest that subclassifying disease progression beyond standard criteria — which typically categorise any tumour growth as “progressive disease” — may provide additional prognostic insight. This could inform discussions about likely trajectories after first-line therapy and help clinicians to tailor follow-up strategies or consider early alternative therapies for patients at higher risk.
HER2 Uncovered: From Low to Ultralow – Get the Low Down with Ben Dessauvagie & Gelareh Farshid
The authors propose that incorporating progression pattern information into radiological assessment frameworks, alongside traditional measures like RECIST (Response Evaluation Criteria in Solid Tumours), may help differentiate patient outcomes more precisely. Further work in broader real-world settings will be needed to confirm how best to use this information in clinical practice.
Paper: Gao, Y., et al. Progressive lesion type is predictive of post-progression survival in first-line chemoimmunotherapy for Non-Small Cell Lung Cancer. Cancer Letters, Volume 639, 2026, 218191. Access online here.
